DNLI - Denali Therapeutics: Key Catalysts Coming Up For This Neurodegenerative Disease Pioneer
Shares of Denali Therapeutics (DNLI) have risen by only 5% since its December 2017 IPO was priced at $18 per share. Year to date, the stock is in the red by about 8%.
Given my rekindled interest in the Parkinson space and desire to have more names on the radar that could achieve proof of concept relatively soon, I listened to management's presentation at Jefferies and was convinced this one deserves more attention.
Chart
Figure 1: DNLI daily advanced chart (Source: Finviz)
When looking at charts, clarity often comes from taking a look